Major U.S. biotech & pharma companies by revenue 2026| ��ƽ��

Leading U.S. biotech and pharmaceutical companies as of March 2026, by revenue (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Release date

March 2026

More information

Region

Worldwide, United States

Survey time period

As of March 2026

Supplementary notes

Including only companies with a headquarters in the United States; subsidiaries of foreign companies are not included. Revenues are global totals.
Release date is the date figures were accessed. The source gives no information if data is based on financial year, calendar year, latest available quarterly results or moving annual total, nor about used exchange rates. All values are total revenues and can include non-pharma/biotech revenues, if a company has a diversified business (e.g., Johnson & Johnson).
FT classifies Cardinal Health as a pharmaceutical company, although it is more a diversified health services and (pharmaceutical) distribution company than a pharmaceutical manufacturer, as the other ranked companies. Thus, it is not included in this ranking.

Citation formats

As of March 2026, Johnson & Johnson was the leading pharmaceutical company in the United States, with a revenue of over ** billion U.S. dollars. Eli Lilly followed with a revenue of ** billion U.S. dollars.

Branded and generic drugs: What are the differences?

Patented products marketed by pharmaceutical companies are referred to as branded. The protection of the patent means that the company, which has spent a large amount of money researching and developing the product, can exclusively sell the drug – often at a high price to recoup its investment. Once the patent expires, other companies may produce generic versions of the product, which contain the same key ingredients.